Gonadorelin Acetate

Hypothalamic-pituitary-gonadal-axis decapeptide · synthetic native GnRH

Per batch COACAS 34973-08-5RUO

Research statusExtensive hormone-receptor literature; this catalogue material is RUO and is not a finished human or veterinary drug

Supplied formDecapeptide (C-terminally amidated)

Lead timeConfirmed with quote

Gonadorelin Acetate — Lyophilized material; confirm released-lot appearance on the COA

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes controlled study of GnRHR signalling, pulse-frequency and continuous-exposure effects, LH/FSH assay responses, salt/counterion qualification and comparison of historical or veterinary finished-product records
These contexts do not establish a TRT adjunct, fertility protocol or veterinary administration use for this RUO lot.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 34973-08-5
Formula: Confirm supplied form on batch COA
Molecular weight: approximately 1242.3 Da
Appearance: Lyophilized material; confirm released-lot appearance on the COA
Purity: Per batch COA
Storage: Store and ship according to the batch COA and validated stability data for the exact free peptide or acetate stoichiometry, formulation, solvent, concentration, container and intended assay. Historical stability results for one bulk or lyophilized formulation do not create a universal room-temperature or 45-day reconstituted dating claim. Avoid unvalidated freeze-thaw cycles and document excursions.
MOQ: On request
Lead time: Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Gonadorelin Acetate

Gonadorelin is synthetic native GnRH/LHRH, a C-terminally amidated decapeptide. Biological response depends on exposure pattern: physiological pulsatile stimulation can release LH and FSH, while sustained exposure can desensitize GnRH receptors. Historical human products and pump systems were developed for diagnostic or reproductive-endocrine uses, and veterinary gonadorelin products remain a separate regulated category. None of those labels authorizes a commercial RUO powder for human use. Free peptide, monoacetate and diacetate records must be distinguished analytically.

Published human evidence supports historical GnRH stimulation testing and pulsatile treatment of selected hypothalamic GnRH-deficiency conditions
These are diagnosis- and protocol-specific clinical contexts, not general fertility, puberty, testosterone-replacement or wellness claims
Veterinary reproductive products have separate species-specific approvals
A historical or veterinary indication does not approve this RUO monoacetate batch.

Mechanism context

The question the literature is testing

Gonadorelin reproduces the native GnRH decapeptide and activates GnRHR on pituitary gonadotrope cells. GnRHR is a G-protein-coupled receptor whose signalling includes phospholipase C, IP3/DAG, intracellular calcium and downstream transcriptional responses. Exposure pattern is biologically important: intermittent stimulation can preserve gonadotropin responses, whereas sustained or high-frequency stimulation can alter receptor abundance, signalling and LH/FSH output. The exact response depends on the model, concentration, pulse width, interval and duration; it should not be reduced to a universal 60-120-minute schedule, a daily microgram amount or a fixed 10-14-day desensitization rule. Historical diagnostic, reproductive-endocrine and veterinary labels apply only to their named finished products.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaHormonal research

Routes reported in sources

SubcutaneousIntravenousIntramuscular

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Sequence identity with endogenous GnRH does not make a commercial RUO lot safe for administration
Historical clinical reports include local or systemic reactions and rare anaphylaxis; continuous and pulsatile exposure have different endocrine consequences
Current US FDA sources identify prescription cattle products with product-specific labels, not authorization for this material
Gonadorelin and related releasing factors are prohibited in male athletes under the 2026 WADA Prohibited List
Handle only under an institutional laboratory protocol.

Interactions reported in the literature

No universal co-administration protocol exists for this RUO product
Literature comparisons with hCG, gonadotropins, testosterone or pulsatile pumps describe different points in the reproductive axis and specific clinical objectives; they do not establish compatibility or stack guidance
Continuous versus pulsatile exposure itself can reverse the direction of the endocrine response, making unsupervised extrapolation especially misleading.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Gonadorelin Acetate factory batch COAs

Gonadorelin Acetate 2 mg Factory batch COA protected preview

Gonadorelin Acetate2 mg · WHJLP-GON2-260522-D

Gonadorelin Acetate 5 mg Factory batch COA protected preview

Gonadorelin Acetate5 mg · WHJLP-GON5-260522-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Visual appearance cannot establish peptide identity, potency, acetate stoichiometry or sterility
Require complete sequence and terminal modifications, explicit free/monoacetate/diacetate form, high-resolution intact mass and sequence-confirming MS/MS or peptide mapping, chromatographic purity with raw data and impurity profile, quantitative peptide content, acetate/counterion and water, residual solvents and lot-specific stability
Sterility, endotoxin and particulates require separate validated testing when claimed
A formula or mass copied from another salt form is a critical release failure.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

GNRH-2MG2 mg10 vials

GNRH-5MG5 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Store and ship according to the batch COA and validated stability data for the exact free peptide or acetate stoichiometry, formulation, solvent, concentration, container and intended assay. Historical stability results for one bulk or lyophilized formulation do not create a universal room-temperature or 45-day reconstituted dating claim. Avoid unvalidated freeze-thaw cycles and document excursions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity and salt distinctions are supported by PubChem records for free gonadorelin, monoacetate and diacetate. Historical pulsatile-GnRH and receptor-response literature supplies scientific context only. FDA's Animal Drugs active-ingredient document, updated July 16, 2026, lists current animal-drug records under gonadorelin, gonadorelin acetate and gonadorelin hydrochloride, while FDA's cattle resource states that the five gonadorelin products it discusses are prescription-only and cattle-specific. FDA's orphan-drug database documents Lutrepulse's historical 1989 gonadorelin-acetate approval; that historical record does not establish current marketing or authorize this RUO lot. The official 2026 WADA Prohibited List explicitly covers gonadorelin and related releasing factors in male athletes. Finished-product labels were not transferred to this RUO material.

01
Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone
New England Journal of Medicine · 1982 · peer-reviewed original research (landmark clinical study)
Open source
02
Pulsatile gonadotropin-releasing hormone therapy in male patients with Kallmann's syndrome or constitutional delay of puberty
Fertility and Sterility · 1985 · peer-reviewed original research
Open source
03
Pulsatile gonadotropin-releasing hormone: clinical applications of a physiologic paradigm
F&S Reports · 2023 · peer-reviewed review
Open source
04
Gonadotropin-releasing hormone: incredible 50 years
F&S Reports · 2023 · peer-reviewed editorial/commemorative review
Open source
05
Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty
Journal of Pediatric Endocrinology and Metabolism · 2015 · peer-reviewed case report
Open source
06
Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review
Annals of Pediatric Endocrinology & Metabolism · 2020 · peer-reviewed mini-review
Open source
07
Gonadorelin Acetate (Generic API product page)
Bachem · 2026 · company technical product page (major peptide API manufacturer)
Open source
08
FDA Approved Animal Drug Products — Active Ingredients
Animal Drugs at FDA · 2026 · U.S. government current animal-drug status document
Open source

Product FAQ

Questions buyers ask about Gonadorelin Acetate

Why must free gonadorelin, gonadorelin acetate and other salt records be distinguished?+

The peptide sequence can be the same while the counter-ion and stoichiometry change the reported formula, molecular-mass basis, assay calculation, water content and material balance. A quotation and COA should state whether the result is calculated as free peptide, a defined acetate form or another salt and should measure or control the counter-ion where it affects release. A name ending in acetate is not sufficient evidence of exact acetate stoichiometry.

What should a decision-ready gonadorelin batch COA include?+

Request sequence or orthogonal identity evidence, chromatographic purity with method conditions, peptide assay or content, the stated free-peptide or salt basis, acetate or other counter-ion where applicable, water, related substances, residual solvents and lot-specific storage and retest information. If a study requires bioburden, endotoxin or sterility attributes, agree them separately; chemical purity and a peptide identity result do not establish a sterile finished medicine.

Gonadorelin Acetate

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Gonadorelin Acetate

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Gonadorelin Acetate factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone

Pulsatile gonadotropin-releasing hormone therapy in male patients with Kallmann's syndrome or constitutional delay of puberty

Pulsatile gonadotropin-releasing hormone: clinical applications of a physiologic paradigm

Gonadotropin-releasing hormone: incredible 50 years

Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty

Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review

Gonadorelin Acetate (Generic API product page)

FDA Approved Animal Drug Products — Active Ingredients

Questions buyers ask about Gonadorelin Acetate

Compare adjacent molecules and documentation needs.

Oxytocin Acetate

ACTH (1-39)

HCG

Menotropins (HMG)